Newly available and recent advances in drug-eluting stents

References

• Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52(14), 1134–1140 (2008).
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27(7), 1500–1510 (2007).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Kolodgie FD, Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev. Med. Devices 6(1), 33–42 (2009).
   PubMed Web of Science ®Google Scholar
• Garg S, Serruys PW. Coronary stents: looking forward. J. Am. Coll. Cardiol. 56(Suppl. 10), S43–S78 (2010).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Joner M et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118(11), 1138–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Finn AV, Garg S, Serruys PW. Coronary stents: current status. J. Am. Coll. Cardiol. 56(Suppl. 10), S1–S42 (2010).
   Google Scholar
• Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120(5), 391–399 (2009).
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193–202 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson GJ, Nakazawa G, Schwartz RS et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-Eluting stents in porcine coronary arteries. Circulation 120(2), 141–149, 141 (2009).
   PubMed Web of Science ®Google Scholar
• Mehilli J, Byrne RA, Wieczorek A et al.; Intracoronary Stenting and Angiographic Restenosis Investigators – Test Efficacy of Rapamycin-eluting Stents with Different Polymer Coating Strategies (ISAR-TEST-3). Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur. Heart J. 29(16), 1975–1982 (2008).
   PubMed Web of Science ®Google Scholar
• Byrne RA, Kastrati A, Kufner S et al.; Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur. Heart J. 30(20), 2441–2449 (2009).
   PubMed Web of Science ®Google Scholar
• Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372(9644), 1163–1173 (2008).
   PubMed Web of Science ®Google Scholar
• Chevalier B, Silber S, Park SJ et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial – Phase 2. Circ. Cardiovasc. Interv. 2, 188–195 (2008).
   Google Scholar
• Barlis P, Regar E, Serruys PW et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur. Heart J. 31(2), 165–176 (2010).
   PubMed Web of Science ®Google Scholar
• Meredith IT, Verheye S, Dubois CL et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J. Am. Coll. Cardiol. 59(15), 1362–1370 (2012).
   PubMed Web of Science ®Google Scholar
• de Abreu-Silva E, Costa R, Seth A et al. First in man safety and performance evaluation of the BIOMIME sirolimus eluting coronary stent system in the treatment of patients with single, de-novo, non-complex coronary lesions – the meriT-1 trial interim report. Presented at: 22nd Transcatheter Cardiovascular Therapeutics (TCT) Conference. San Francisco, CA, USA, 7–11 November 2011.
   Google Scholar
• de Abreu-Silva E, Costa R, Seth A et al. Impact of the new BioMime™ sirolimus-eluting stent in comlex patients of daily practice. Preliminary results of the MeriT-2 study. J. Am. Coll. Cardiol. 60(17s), B189 (2012).
   Google Scholar
• Lamos P. A trial of bare metal stent – cobalt chromium versus stent coating with sirolimus (INSPIRON). Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Gao R. TARGET I: a prospective, randomized trial of a bioabsorbable polymer-based sirolimus-eluting stent vs. an everolimus-eluting stent. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Dani S. Abluminus™ DES ‘enABL’ program update. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Windecker S. Study of the Orsiro drug eluting stent system (BIOFLOW-II). Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Wijns W, Vrolix M, Verheye S et al. Nine month imaging and twelve month clinical results from the DESSOLVE II Randomized Trial of the MiStent® SES with absorbable polymer. J. Am. Coll. Cardiol. 60(17s), B169 (2012).
   Google Scholar
• Abizaid A, Botelho A, Schofer J et al. Multicenter, prospective, randomized, single blind, consecutive enrollment evaluation a novolimus-eluting coronary stent system with bioabsorbable polymer compared to a zotarolimus-eluting coronary stent system: 12-month clinical and 6-month angiographic and IVUS results: the EXCELLA BD Study. J. Am. Coll. Cardiol. 60(17s), B169 (2012).
   Google Scholar
• Carrié D, Berland J, Verheye S et al. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions. J. Am. Coll. Cardiol. 59(15), 1371–1376 (2012).
   PubMed Web of Science ®Google Scholar
• Carrie D. Cre8 Program Update. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Urban B. BioFreedom Program Update. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Mehilli J. Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis (ISAR-TEST-5). Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Abizaid A, Costa R, Seth A et al. One-year results of the multicentric double-blinded randomized VESTASYNC II trial. J. Am. Coll. Cardiol. 58(20s8), B62 (2011).
   Google Scholar
• Costa R. Amazonia PAX Program Update. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Chevalier B, Silber S, Park SJ et al.; NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial – Phase 2. Circ. Cardiovasc. Interv. 2(3), 188–195 (2009).
   PubMed Web of Science ®Google Scholar
• Kadota K, Muramatsu T, Iwabuchi M et al. Randomized comparison of the Nobori Biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter. Cardiovasc. Interv. 80(5), 789–796 (2012).
   PubMed Web of Science ®Google Scholar
• Chevallier B. Nobori clinical update. Presented at: EuroPCR Congress. Paris, France, 17–21 May 2011.
   Google Scholar
• Serruys P, Buszman P, Linke P et al. LEADERS: 5-Year Follow-Up from a prospective, randomized trial of biolimus A9-eluting stents with a biodegradable polymer vs. sirolimus-eluting stents with a durable polymer – final report of the LEADERS study. J. Am. Coll. Cardiol. 60(17S) (2012).
   Google Scholar
• Lee CW, Park DW, Seung KB et al. Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions. Am. J. Cardiol. 107(7), 990–994 (2011).
   PubMedGoogle Scholar
• Sakata K, Nakatani D, Waseda K et al. First-In-Man IVUS Findings of the Prohealing PROTEXTM Coronary Stent System for the Treatment of Coronary Artery Disease. J. Am. Coll. Cardiol. 58(20s8), B63 (2011).
   Google Scholar
• Haude M. The REMEDEE study: a randomized comparison of a combination sirolimus eluting EPC capture stent with a paclitaxel eluting Stent. J. Am. Coll. Cardiol. 59(13s1), E209 (2012).
   Google Scholar
• Landmesse U, Wijns W, Barbato E et al. The REMEDEE OCT study: a prospective randomized study of the early vascular healing of a novel dual therapy stent in comparison with an everolimus eluting stent. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Aggarwal RK, Ireland DC, Azrin MA, Ezekowitz MD, de Bono DP, Gershlick AH. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation 94(12), 3311–3317 (1996).
   PubMed Web of Science ®Google Scholar
• Ng M, Waterhouse A, Yin Y et al. Immobilized recombinant human tropoelastin on a plasma-activated coating dramatically enhances biocompatibility of metal alloys: implications for coronary stents. J. Am. Coll. Cardiol. 58(20s8), B50, (2011).
   Google Scholar
• Zhao JL, Sun BG, Wen QZ. Effects of control-releasing arsenic trioxide-eluting stent on intimal smooth muscle cells and type III collagen in canine coronary artery post-stent model. Zhongguo Zhong Xi Yi Jie He Za Zhi 30(6), 636–639 (2010).
   Google Scholar
• Masuda S, Nakano K, Funakoshi K et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J. Atheroscler. Thromb. 18(12), 1043–1053 (2011).
   Google Scholar
• Wilcox J. Progress with a hollow-core rapamycin-filled stent. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Seth A. Nanoparticle Based Stents – FOCUS np™ (Envision Scientific) program update. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Costa R. Mitsu (Meril Life Sciences) program update. Presented at: 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Costa J, Kopia G, Stanley J et al. One-year preclinical data on a novel drug-eluting stent with amino acid-based bioabsorbable drug carrier mounted on an integrated delivery system (IDS). J. Am. Coll.Cardiol. 60(17s), (2012).
   Google Scholar
• Nishio S, Kosuga K, Igaki K et al. Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki–Tamai stents. Circulation 125(19), 2343–2353 (2012).
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371(9616), 899–907 (2008).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667), 897–910 (2009).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Onuma Y, Ormiston JA et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122(22), 2301–2312 (2010).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Onuma Y; on behalf of the ABSORB A & B investigators. ABSORB Cohort B: 6 m, 12 m, 18 m and 24 m follow-up. PCR focus group on bioresorbable vascular scaffolds. Rotterdam, The Netherlands, March 2012.
   Google Scholar
• Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58(15), 1578–1588 (2011).
   PubMed Web of Science ®Google Scholar
• Ghimire G, Spiro J, Kharbanda R et al. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention 4(4), 481–484 (2009).
   PubMed Web of Science ®Google Scholar
• Haude M. From PROGRESS to DREAMS. PCR focus group on bioresorbable vascular scaffolds. Rotterdam, The Netherlands, March 2012.
   Google Scholar
• Waksman R. Lessons learned from preclinical studies of magnesium scaffolds (Biotronik’s DREAMS program). PCR focus group on bioresorbable vascular scaffolds. Rotterdam, The Netherlands, March 2012.
   Google Scholar
• Ielasi A, Latib A, Colombo A. Current and future drug-eluting coronary stent technology. Expert Rev. Cardiovasc. Ther. 9(4), 485–503 (2011).
   PubMedGoogle Scholar